A salt represented by formula (I): ##STR00001##
wherein Q.sup.1 and Q.sup.2 each independently represent a fluorine atom or a C.sub.1 to C.sub.6 perfluoroalkyl group, R.sup.1 and R.sup.2 each independently represent a hydrogen atom, a fluorine atom or a C.sub.1 to C.sub.6 perfluoroalkyl group, z represents an integer of 0 to 6, X.sup.1 represents *—O—, *—CO—O— or *—O—CO—, * represents a binding site to CR.sup.1R.sup.2 or CQ.sup.1Q.sup.2, L.sup.1 represents a C.sub.1 to C.sub.6 alkanediyl group, R.sup.3 represents a C.sub.5 to C.sub.18 alicyclic hydrocarbon group in which a hydrogen atom may be replaced by a hydroxy group, and in which a methylene group may be replaced by an oxygen atom or a carbonyl group, and which alicyclic hydrocarbon group may have a cyclic ketal structure optionally having a fluorine atom; and Z.sup.+ represents an organic cation.

A salt represented by formula (I): ##STR00001##
wherein Q.sup.1 and Q.sup.2 each independently represent a fluorine atom or a C.sub.1 to C.sub.6 perfluoroalkyl group, R.sup.1 and R.sup.2 each independently represent a hydrogen atom, a fluorine atom or a C.sub.1 to C.sub.6 perfluoroalkyl group, z represents an integer of 0 to 6, X.sup.1 represents *—O—, *—CO—O— or *—O—CO—, * represents a binding site to CR.sup.1R.sup.2 or CQ.sup.1Q.sup.2, L.sup.1 represents a C.sub.1 to C.sub.6 alkanediyl group, R.sup.3 represents a C.sub.5 to C.sub.18 alicyclic hydrocarbon group in which a hydrogen atom may be replaced by a hydroxy group, and in which a methylene group may be replaced by an oxygen atom or a carbonyl group, and which alicyclic hydrocarbon group may have a cyclic ketal structure optionally having a fluorine atom; and Z.sup.+ represents an organic cation.

Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

##STR00001##

A resist composition containing a base material component (A) of which solubility in a developing solution is changed due to an action of an acid and a compound represented by Formula (bd1); in the formula, R.sup.bd1 to R.sup.bd3 each independently represent an aryl group which may have a substituent, provided that at least two of R.sup.bd1 to R.sup.bd3 are aryl groups having one or more fluorine atoms as substituents, and at least one of the fluorine atoms of the aryl group is bonded to a carbon atom adjacent to a carbon atom that is bonded to the sulfur atom in the formula, and the total number of the fluorine atoms is 4 or more; X.sup.− represents a counter anion. ##STR00001##

A resist composition containing a base material component (A) of which solubility in a developing solution is changed due to an action of an acid and a compound represented by Formula (bd1); in the formula, R.sup.bd1 to R.sup.bd3 each independently represent an aryl group which may have a substituent, provided that at least two of R.sup.bd1 to R.sup.bd3 are aryl groups having one or more fluorine atoms as substituents, and at least one of the fluorine atoms of the aryl group is bonded to a carbon atom adjacent to a carbon atom that is bonded to the sulfur atom in the formula, and the total number of the fluorine atoms is 4 or more; X.sup.− represents a counter anion. ##STR00001##

The present application provides compounds and methods for treating bacterial infections, including bacterial infections caused by MRSA.

The present application provides compounds and methods for treating bacterial infections, including bacterial infections caused by MRSA.

A light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission part disposed between the first electrode and the second electrode and including a first emission layer and a second emission layer disposed on the first emission layer, the first emission layer may include a first host, and a first dopant, and the second emission layer may include a hole transport host different from the first host, an electron transport host, and a second dopant. A first hole mobility of the first host may be in a range of about 5.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−3 cm.sup.2/Vs, a second hole mobility of a host mixture including the hole transport host and the electron transport host may be in a range of about 1.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−4 cm.sup.2/Vs, and the first hole mobility may be larger than the second hole mobility.

A light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission part disposed between the first electrode and the second electrode and including a first emission layer and a second emission layer disposed on the first emission layer, the first emission layer may include a first host, and a first dopant, and the second emission layer may include a hole transport host different from the first host, an electron transport host, and a second dopant. A first hole mobility of the first host may be in a range of about 5.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−3 cm.sup.2/Vs, a second hole mobility of a host mixture including the hole transport host and the electron transport host may be in a range of about 1.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−4 cm.sup.2/Vs, and the first hole mobility may be larger than the second hole mobility.

A liquid lens fluid composition includes a polyphenyl ether molecule having from 2 to 7 aromatic rings, where the rings include ortho substitutions, meta substitutions, or a combination of ortho, meta, and para substitutions. Inter-ring linkages may include sulfur or oxygen. The liquid lens fluid composition may be characterized by a refractive index over the visible spectrum of at least 1.4, a viscosity at room temperature of less than approximately 1000 cP, and a freezing point of less than approximately −10° C.